secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cue Biopharma, Inc. (CUE)
CIK:        0001645460
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0000950170-24-127004
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cue Biopharma Q3 net loss narrows to $8.7M; CUE-101 combo shows 46% ORR in HPV+ HNSCC
--------------------------------------------------------------------------------

- Net loss of $8.7M ($0.17 per share) vs $11.0M loss ($0.24) in Q3 2023; collaboration revenue rose to $3.3M.
- Cash $32.4M, expected to fund operations into Q4 2025; $12M public offering priced in quarter.
- CUE-101 + KEYTRUDA Phase 1 data: 46% ORR, 91.3% 12-month OS, 21.8-month mOS in 1L HPV+ HNSCC.
- CUE-102 monotherapy: 67% DCR in late-stage pancreatic cancer; favorable tolerability with no DLTs.
- Appointed Lucinda Warren as Chief Business Officer; preclinical autoimmune programs advancing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645460/000095017024127004/0000950170-24-127004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645460/000095017024127004/cue-20241114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-127004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer